Insight Molecular Diagnostics Inc. — Director's Dealing 2022

Aug 19, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Oncocyte Corp (OCX)
CIK: 0001642380
Period of Report: 2022-08-17

Reporting Person: Arno Andrew (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-08-17	Common Stock, no par value	P	7500	$0.90	Acquired	15000	Indirect
2022-08-17	Common Stock, no par value	P	7500	$0.90	Acquired	15000	Indirect

Footnotes

F1: The price of $0.90 per share represents a weighted average of prices ranging from $0.88 to $0.92 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: The shares of common stock are held by JBA Investments LLC. The Reporting Person is the Manager of JBA Investments LLC and in such capacity has the right to vote and dispose of the securities held by such entity.

F3: The shares of common stock are held by MJA Investments LLC. The Reporting Person is the Manager of MJA Investments LLC and in such capacity has the right to vote and dispose of the securities held by such entity.